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Symptoms at presentation for treatment in patients with lung cancer:
implications for the evaluation of palliative treatment
P Hopwood' and RJ Stephens2 on behalf of the Medical Research Council (MRC) Lung
Cancer Working Partya
'CRC Psychological Medicine Group, Christie Hospital, Manchester M20 4BX, UK; 2MRC Cancer Trials Office, 5 Shaftesbury
Road, Cambridge CB2 2BW, UK.
S_qy The ten most frequently reported pretreatment symptoms on the Rotterdam Symptom Checklst,
which was completed by more than 650 patients entering two MRC Lung Cancer Working Party multicentre
randomised trials, iuded geral symptoms (t ness, lack of appetite) and psychological distress (worry,
anxiety) in adfition to diease-reled chest symptoms (cough, shortness of breath). Although the number and
severity of symptoms incresed with worsening performance status, the commonest symptoms were found to
be vilually the same for patints with small-cell hmg cacer (SCLC) and non-small-Il lung caer (NSCLC),
and for dfferent grades of performance status. Women with NSCLC reported more psychological symptoms
than maks, but this difference was much less evident in patients with SCLC. Thus, in order to asses fully the
benefit of paliative treatments in patients with hmg caer, account must be taken of al symptoms at
presentation, in addition to the traditionally recognised chest symptoms.
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In patients with advanced lung cancer for whom cure is
considered unlikely, pallation of symptoms becomes the
prime therapeutic objective. Although ther has been much
discussion about the need for quality of life (QL) end points
in randomised trials ofpallative treatment, there are still few
publications which actually present such data. To date, the
effiacy of different palliative regimens has largly been
judged by resonse to treatment, s l time, toxicity and
performance status (Minet et al., 1987; Thatcher et al., 1987;
Cullen et al., 1988; Ferandez et al., 1989). Performance
status has been used as a proxy measure of QL, but as such
is an inadequate measure because of its unidimensional
nature. Its use has proved controversial, because of reported
insenstivity to change with worsening toxicity (Geddes et al.,
1990) and poor correlation with both psychosocial well-being
(Schipper et al., 1984) and symptom prevalec (Mor et al.,
1984). Surprisingly, relief of key hlng ancer symptoms
(shortness of breath, cough, chest pain and haemoptysis) has
not been routinely reported, although these form the basis
for intervention. Thus, in a review of trials for non-small-cell
lung cancer conducted by the Easten Cooperative Oncology
Group involving 3000 patients, no mention of symptoms was
made, although the paper addr the issue of risks and
benefits in cinical trials and endorsed the importance of
quality of survival (Simes, 1985).
Most studies of symptoms have been carTied out in the
tminal care setting, in heterogeneous cancer patient groups
and have focused on problems such as pain, which has been
reported as the commonest symptom in advanced caer
(Curtis et al., 1991), although recently the disruptive effect of
general symptoms was highlighted in a study of women with
lung cancer (Sama, 1993). More speifically, Krech et al.
(1992) described symptoms in 100 patients with lung cancer
(90% non-small-cell) referred to a palliative care service.
Using an in-house assessment tool completed by one of the
nursing or medical team, the reported top ten symptoms
rated moderate or severe were pain, dyspnoea, weight loss,
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anorexia, constipation, easy fatigue, weakness, early satiety,
sleep problem and lack of energy. The median number of
symptoms was 9, and as expected there was a general in-
crease in the number of symptoms with worsening perfor-
mance status.
Symptoms associated with cancer can cause considerable
distess, and hence symptom control is an essential part of
cancer care. Moreover, symptom assessent is becoming an
essential component ofaudit in pallative care (Vainio, 1993).
If trials are to compare palliative treatments adequately and
enable ciians to discuss the advangs and disadvantages
of treatment options with their patients, there needs to be
much greater awareness of the nature, number and severity
ofsymptoms and concerns at the outset and oftheir response
to therapy. The overall well-being of patients undergoing
treatment and the impact of adverse effects can then be
adequately judged. Moreover, psychosocial well-being has
been suggested as a positive prognostic factor in non-small-
cell lung cancer (Kaasa et al., 1989; Muers and Round,
1993), while malaise and anorexia may be indicators of a
poor prognosis (Muers and Round, 1993). Such data should
be generated by patients themselves however, since obsrms'
opinions have been shown to be different from those of
patiets (Osoba, 1994). To date there has been no published
account of the generaLity of symptoms at presentation in
patients with lung cancer as reported by patients
themselves.
Aim
We examined the symptoms at presentation for treatment in
patients entered in two recent multicentre randomised clinical
trials of lung cancer conducted by the Medical Research
Council (MRC) Lung Cancer Working Party (MRC 1994a,
b) to assess and compare the range and prevalen of symp-
toms in small-cel lung ancer (SCLC) and non-small-cell
lung cancr (NSCLC). The effect of gender and performance
status on reporting symptoms was also examined within each
trial sample.
Mateil and A
The two trials were as follows: LU12 was a comparison of
two chemotherapy policies for patients with SCLC and atos at pes al i in lung cancer
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poor prognosis. A total of 310 patients were entered from 23
centres in the UK between November 1989 and September
1992. The median age of these patients was 65 years (range
39-90). 63% were male. and on admission 72% had exten-
sive disease and 52% had a WHO performance status (PS) of
3 or 4. LU13 was a comparison of two radiotherapy policies
for patients with inoperable NSCLC and a good performance
status. A total of 509 patients were entered from 11 centres
in the UK between November 1989 and October 1992. Their
median age was 66 years (range 33-89), 79% were male,
79% had squamous histology. and on admission 78% had a
WHO performance status of 0 or 1.
The symptoms assessed were included in a patient self-
report measure of QL, the Rotterdam Symptom Checklist
(RSCL), which has been used as an integral part of the data
collection in such trials. The RSCL is a patient-completed
questionnaire containing a core of 30 symptoms covering a
number of domains (physical, psychological and sexual), to'
which five items had been added: four symptoms specific to
lung cancer (cough. haemoptysis, chest pain and hoarseness)
and one further item (restlessness), which was being tested as
a component of the psychological subscale (Frith, 1992).
Eight additional questions relating to activities of daily living
were also routinely completed. but this subscale has not been
included in this analysis. Patients completed the RSCL ac-
cording to how they were feeling during the previous week,
and in both trials the questionnaire was first administered at
the time of randomisation. but before any treatment had
been given. The full QL analyses for each trial, including
explorations of the changes over time, will be reported
elsewhere.
Results
In LU12 (SCLC), 232 (75%) of the 310 patients completed
an RSCL questionnaire at the time of randomisation, and in
LU13 (NSCLC). 423 (83%) of the 509 patients. The
prevalence and severity of the reported symptoms in LU12
are shown in Figure 1 in decreasing order of prevalence.
Figure 2 shows the prevalence and severity of symptoms for
LU13 in the same order as Figure 1.
The overall pattern of symptom prevalence was very
similar for the two disease groups, the only major differences
being the higher levels of chest pain and coughing up blood
reported in LU13. Apart from chest pain, which ranked sixth
in LU13 and 20th in LU12, the eight commonest symptoms
in both patient groups were the same. and consisted of
symptoms from a variety of domains: psychological (worry-
ing and anxious feelings), general (tiredness, lack of energy,
lack of appetite and difficulty sleeping) and chest symptoms
(shortness of breath and cough). Similarly, the symptoms
most frequently reported as severe were the same in the two
groups, and came from different domains, the three com-
monest being decreased sexual interest, lack of energy and
shortness of breath.
There was a difference between the groups in terms of the
number of symptoms reported. Patients in LU12 (SCLC)
reported, on average, 17.4 symptoms (8.9 mild, 4.3 moderate
and 4.2 severe) and those in LU13 (NSCLC) reported 14.3
symptoms (8.6 mild. 3.4 moderate and 2.3 severe). The
different levels of reported moderate and severe symptoms
can be observed by comparing Figures 1 and 2. Within each
group, the number of symptoms increased with worsening
performance status. Thus, in LU12 (SCLC) the number of
symptoms increased from an average of 15.6 in patients with
PS grade 0 or 1 to 18.3 in patients with grade 3 or 4, and
similarly in LU13 the number of symptoms increased from
11.6 in patients with grade 0 to 15.9 with grade 2. There
appeared to be no consistent pattern of symptoms or
domains relating to these increases, although in both groups
the number of patients reporting lack of appetite increased
the most, while the number reporting cough actually
decreased slightly. The largest change between the subgroups
of patients with different PS grades appeared to be in the
number of severe symptoms reported; thus, in LU12 (SCLC)
the number of severe symptoms increased from 2.7 to 4.8,
and in LU13 from 0.9 to 3.9.
The effect of gender was less clear. In LU13 (NSCLC)
females reported an average of 16.8 symptoms (9.9 mild, 3.8
moderate and 3.2 severe) compared with the males' 13.8 (8.3
mild, 3.4 moderate and 2.1 severe). The prevalence of general
symptoms was similar, but females reported much higher
levels of psychological symptoms, with an absolute difference
of >20% in feeling tense, nervousness, anxious feelings,
despondent feelings, worrying, depressed mood and restless-
ness. The few symptoms in which males reported slightly
higher levels than females tended to be the disease-specific
physical symptoms, 12% more coughing up blood, 7% more
cough, 3% more loss of hair, 3% more shortness of breath
and 2% more chest pain. In LU12 (SCLC), however, males
reported on average 17.9 symptoms (9.4 mild, 4.5 moderate
and 3.9 severe) compared with the mean prevalence for
females of 16.7 (8.1 mild, 4.0 moderate and 4.6 severe)
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and no clear patterns of differences between the various
domains were observed.
Discon
Although the prevalence of specific symptoms will differ
according to the instrument used, and by whom it is com-
pleted, one would expect to see similar patterns emerge
overall. However, our data, based on a patient self-report
scale, included more psychological symptoms - worry.
anxiety. tension and despondency about the future - than the
study reported by Krech et al. (1992) using reports by
medical or nursing staff. It is recognised, however, that such
symptoms are frequently undetected by clinicians (Hopwood,
1992). There was similanrty with Krech et al.'s data in the
incidence of five physical symptoms, but, whereas pain was
their most frequently observed symptom, it was not among
the ten most prevalent in our analysis suggesting a difference
in both patient samples and observer-patient perceptions of
symptoms.
With respect to gender. the increased reporting of
psychological symptoms in women with NSCLC was not
unexpected, since it is known that there is a higher
prevalence of psychological illness in women than in men,
and this accounted for much of the difference in overall
number of symptoms in the trial. Surprisingly, this finding
was not repeated in the SCLC trial. Curtis et al. (1991) failed
to find an effect of gender on the overall number of symp-
toms in their small heterogeneous cancer sample, but our
inconsistent findings in two large homogeneous groups sug-
gest that it may be unwise to generalise results based on
small numbers of patients with differing cancer sites. Never-
theless, our observation that the pattern of symptom
prevalence was constant across patients with different perfor-
mance status means that the need to take a broad approach
has general application.
The prevalence of key physical symptoms in our sample of
patients with NSCLC is comparable with that reported by
Muers and Round (1993) using a similar assessment method,
but in considering only physical indices (and excluding
tiredness and lack of energy) they address only one aspect of
palliation. Greater importance of chest symptoms is inevit-
ably inferred by this method of presenting data, yet the
outcome of treatment can be described by a variety of
different QL end points (physical, functional, psychosocial),
which may, in turn, give conflicting information (Earl et al.,
1991; Richards et al., 1992; Holl and Hakama, 1993).
Clearly, while disease-related symptoms are a necessary
focus for anti-cancer therapy, and their palliation an
indicator of the success of the therapy, there are other impor-
tant symptoms and markers of psychological distress that
should cause concern and alert health professionals to the
need for intervention (e.g. psychological support). One
important aspect of QL research is to increase awareness of
the variety of symptoms reqiiring treatment, especially in the
palliative setting. Little is yet known about the relative
impact on the patient of specific symptoms such as fatigue
(which may seriously compromise function) or haemoptysis
(which may cause considerable alarm and signify active
disease) or the way in which symptoms interact (e.g. pal-
hating cough may also decrease anxiety and worry). Other
issues also warrant further research, such as assessing
clinically meaningful changes from questionnaire data and
distinguishing effects of treatment on QL from those attri-
butable to the disease.
In our sample, the ranking of the top four symptoms
remained unchanged when a second cross-section of the data
was examined I month before death. Longitudinal analyses
will inform us of the extent of palliation and change in
severity of symptoms over time, but these data suggest that
pretreatment symptoms are an important indicator of aspects
of well-being that will require continued assessment and
intervention.
The implications for the evaluation of new treatments
designed to palliate lung cancer is that a much wider range of
symptoms need to be assessed and monitored before treat-
ments can be claimed to provide effective palliation.
Knowledge of symptom profiles and patterns of change may
help health care professionals prevent as well as relieve dis-
tress, and provide optimum palliative care.
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